Adam Szulkin
Papers
1
Total Citations
35
H-Index
1
About
Adam Szulkin is a cancer researcher whose work focuses on malignant mesothelioma, a rare and aggressive cancer with limited treatment options. His major contributions center on improving therapeutic strategies through patient-derived models, particularly by characterizing primary malignant mesothelioma cells from pleural effusions. In his most cited work (2014, 35 citations), Szulkin developed an ex vivo chemosensitivity assay to test drug responses in these primary cells, aiming to predict the most effective treatments for individual patients—a step toward personalized oncology in a disease where only 40% respond to standard pemetrexed-cisplatin therapy. This research bridges the gap between laboratory science and clinical application, offering a tool to optimize first-line treatment selection. Szulkin’s work has been instrumental in advancing our understanding of mesothelioma biology and drug resistance, with his citation impact reflecting the relevance of his findings to both basic researchers and clinicians. His efforts contribute to a growing movement toward precision medicine in thoracic oncology, where tailoring therapy to a patient’s unique tumor profile could improve outcomes in this challenging disease.
Research Focus
Key Achievements
Top Papers
- 1